Oppenheimer lowered the firm’s price target on Perspective Therapeutics (CATX) to $13 from $14 and keeps an Outperform rating on the shares following the company’s Q3 business update on Monday afternoon. The update follows recent positive results for VMT-alpha-NET presented at ESMO, with Perspective down 29% on the day, after competitor Sanofi (SNY)/Oranomed presented updated Alphamedix02 results with a 60% ORR in the same session. In Oppenheimer’s view key differences between the studies make this a more competitive story than the headline numbers suggest, keeping the firm cautiously optimistic.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Reports Promising Q3 2025 Results
- Perspective Therapeutics reports Q3 EPS (35c), consensus (32c)
- Perspective Therapeutics Updates Corporate Presentation on Pipeline
- Perspective Therapeutics Updates Executive Employment Agreements
- Perspective Therapeutics Advances in Neuroendocrine Tumor Therapy with Promising Clinical Study